DHC Diversified Healthcare Trust
Diversified Healthcare Trust is a real estate investment trust, or REIT, focused on owning high-quality healthcare properties located throughout the United States. DHC's portfolio is anchored by a strategically curated mix of senior housing, medical office and life science assets that combine high quality care, modern technology and amenity rich environments to meet rising demand across the healthcare continuum. As of September 30, 2026, DHC's approximately 6.3 billion dollar portfolio included 285 properties in 33 states and Washington, D.C., with 23,773 senior living units, approximately 5.6 million square feet of medical office and life science properties and occupied by approximately 250 tenants. DHC is managed by The RMR Group, a leading U.S. alternative asset management company with over 37 billion dollar in assets under management as of September 30, 2026 and 40 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, Massachusetts. Diversified Healthcare Trust was established in 1998 and is incorporated in Maryland.…
Industry Peers
REIT - Healthcare FacilitiesKey Statistics
About Diversified Healthcare Trust (NASDAQ: DHC)
›
Diversified Healthcare Trust (NASDAQ: DHC) is listed on Nasdaq, where its shares trade in USD. It belongs to the REIT - Healthcare Facilities industry, part of the Real Estate sector.
The shares were at 7.050 USD on 20 November 2026, up 58.2% over 52 weeks. Its 52-week range is 4.340 USD to 9.660 USD: the price is 27.0% below the high and 62.4% above the low.
Its market capitalisation is 1.71B USD. It pays a dividend yielding 0.57% (it pays out 2% of its earnings), against a median of 5.81% among the dividend payers in that peer group.
Diversified Healthcare Trust reports return on equity of -17.2%, an operating margin of -1.1% and revenue down 5.4% year over year.
Its debt exceeds its cash by 2.31B USD, a debt-to-equity ratio of 1.44. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 9.875 USD is 40.1% above the current price. The next earnings report is expected on 22 February 2027.